Display Settings:

Format

Send to:

Choose Destination

    Ugeskr Laeger. 2005 Aug 8;167(32):2903-4.

    [Activation of psoriasis in patients undergoing treatment with interferon-beta]

    [Article in Danish]

    Navne JE, Hedegaard U, Bygum A.

    Odense Universitetshospital, Dermato-venerologisk Afdeling I, og Laegemiddelinformationscentralen, Afdeling KKA.

    Psoriasis is a chronic, inflammatory skin disorder that is induced and aggravated by a number of endogenous and exogenous factors. Traditionally lithium, beta blockers, NSAIDs, ACE inhibitors and antimalarials have been associated with psoriasis, but interferon can also be a triggering factor. We present two patients with multiple sclerosis who suffered from activation of psoriasis in relation to interferon-beta treatment. In one of the patients, psoriasiform injection site lesions persisted six years after termination of the interferon treatment.

    PMID: 16109199 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Patient drug information

    • Lithium (Eskalith CR®, Eskalith®, Lithobid®)

      Lithium is used to treat and prevent episodes of mania (frenzied, abnormally excited mood) in people with bipolar disorder (manic depressive disorder; a disease that causes episodes of depression, episodes of mania, and ...